Regression of Basal Cell Carcinomas in Multiple Sclerosis Patient on Aubagio Treatment

Judy Park DeWitt; Kleesy L Thomas; Ashley Sturgeon

doi:10.12746/swrccc.v5i21.414

Regression of Basal Cell Carcinomas in Multiple Sclerosis Patient on Aubagio Treatment

Judy Park DeWitt School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas
Kleesy L Thomas Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas
Ashley Sturgeon Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas

DOI: https://doi.org/10.12746/swrccc.v5i21.414

Keywords: Basal Cell Carcinomas, Multiple Sclerosis, Teriflunomide, Aubagio

Downloads

Download data is not yet available.

References

Soyer H, Rigel D, Wurm E. Actinic Keratosis, Basal Cell Carcinoma and Squamous Cell Carcinoma. In: Bolognia J, Jorizzo J, Schaffer J. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders. 2012:108:1773-1793.

Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74:659-674.

Huang O, Zhang W, Zhi Q, et al. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Experimental biology and medicine. 2015;240:426-437.

Published

2017-10-16

How to Cite

DeWitt, J. P., Thomas, K. L., & Sturgeon, A. (2017). Regression of Basal Cell Carcinomas in Multiple Sclerosis Patient on Aubagio Treatment. The Southwest Respiratory and Critical Care Chronicles, 5(21), 55-56. https://doi.org/10.12746/swrccc.v5i21.414

Download Citation

Issue

Vol 5 No 21 (2017): The Southwest Respiratory and Critical Care Chronicles

Section

Letter to the Editor